These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35579771)

  • 41. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
    Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
    Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.
    Tahija SG; Hersetyati R; Lam GC; Kusaka S; McMenamin PG
    Br J Ophthalmol; 2014 Apr; 98(4):507-12. PubMed ID: 24403566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity.
    Sternfeld A; Rahmani S; Rossen JL; Zhang DL; Li YD; Quan VL; Huang R; Yoon HH
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1915-1921. PubMed ID: 34851464
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy.
    Hondur AM; Çubuk MÖ; Özen Tunay Z; Atalay HT; Özdemir Ö; Petriçli İS; Gürelik İG
    Turk J Med Sci; 2016 Apr; 46(3):764-8. PubMed ID: 27513253
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity.
    Sindal MD; Nagesha CK; Yadav D; Fazal R
    Lasers Med Sci; 2022 Jul; 37(5):2501-2508. PubMed ID: 35106690
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
    Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC
    Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment.
    Lee YS; See LC; Chang SH; Wang NK; Hwang YS; Lai CC; Chen KJ; Wu WC
    Am J Ophthalmol; 2018 Aug; 192():20-30. PubMed ID: 29753851
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.
    Chen TA; Shields RA; Bodnar ZH; Callaway NF; Schachar IH; Moshfeghi DM
    Am J Ophthalmol; 2019 Feb; 198():63-69. PubMed ID: 30312578
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study.
    Morrison D; Shaffer J; Ying GS; Binenbaum G;
    J AAPOS; 2018 Apr; 22(2):128-133. PubMed ID: 29548840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
    Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
    Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity.
    Simmons M; Wang J; Leffler JN; Li S; Morale SE; de la Cruz A; Birch EE
    Transl Vis Sci Technol; 2021 Apr; 10(4):14. PubMed ID: 34003992
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1.
    Kimyon S; Mete A
    Ophthalmologica; 2018; 240(2):99-105. PubMed ID: 29920490
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
    Toy BC; Schachar IH; Tan GS; Moshfeghi DM
    Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of intravitreal bevacizumab monotherapy and combined laser photocoagulation and intravitreal bevacizumab therapy in the same session in the treatment of aggressive retinopathy of prematurity.
    Sabancı Ş; Küçük MF; Süren E; Erol MK
    Int Ophthalmol; 2024 Jul; 44(1):305. PubMed ID: 38954120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity.
    Mori Y; Arima M; Ueda E; Fujiwara K; Seki E; Nakama T; Tsukamoto S; Akiyama M; Sonoda KH
    Eye (Lond); 2021 Oct; 35(10):2820-2825. PubMed ID: 33257802
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravitreal bevacizumab monotherapy for retinopathy of prematurity.
    Şahin A; Şahin M; Cingü AK; Çınar Y; Türkcü FM; Yüksel H; Kaya S; Arı Ş; Caça İ
    Pediatr Int; 2013 Oct; 55(5):599-603. PubMed ID: 23659781
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.
    Nazari H; Modarres M; Parvaresh MM; Ghasemi Falavarjani K
    Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1713-8. PubMed ID: 20582706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Refractive outcomes following unilateral laser treatment for type 1 retinopathy of prematurity.
    Bayramoglu SE; Sayin N; Ekinci DY
    J AAPOS; 2022 Oct; 26(5):245.e1-245.e6. PubMed ID: 36113701
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anatomical and refractive outcomes in patients with treated retinopathy of prematurity.
    Lolas M; Tuma A; Zanolli M; Agurto R; Stevenson R; Ossandón D
    Arch Soc Esp Oftalmol; 2017 Oct; 92(10):472-476. PubMed ID: 28624314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.